Ready for Any Challenge
Profile: Adeka Pharmaceuticals
Within a year of its establishment as a local family company in 1956, Adeka was already forging partnerships with international
pharmaceutical companies, registering, importing, manufacturing and distributing products to the Turkish market. It's the
hallmark of a company that has utilized its outward thinking to become one of the 15 largest Turkish pharmaceutical companies,
with 2007 sales reaching $100 million.
Ali Cüneyt Arpacıoğlu, (All photos are courtesy of EC Reviews.)
Adeka produces its own line of generics and also represents 11 companies—from Europe and the United States—in exclusive licensing
deals. Its product portfolio focuses on cardiology, gynecology, dermatology, pediatrics, and the central nervous system, a
strategy that helps it rely on niche therapeutics and stay away from intensely competitive generics areas. The company's success
derives from the diversity of its products, says Ali Cüneyt Arpacioglu, Adeka's CEO and president.
Looking forward, Adeka has created a mid-term vision that accepts industry realities and confronts all competitive threats,
those within Turkey and from booming generics markets like India and China. Arpacioglu says the company is "going to be stronger
in the current fields," by increasing the number of "value-added" products in dermatology, gynecology and pediatrics, and
by launching as many as four new combinations in cardiology. Adeka has also recently penetrated the nutraceuticals and self-medication
market with distinctive products, and Arpacioglu says there are more to follow.
Making Strides in Major Markets
Profile: Mustafa Nevzat Pharmaceuticals
Relying on a strong antibiotics franchise and varied generics portfolio, Mustafa Nevzat has climbed steadily to the upper
ranks of the Turkish pharmaceutical sector, reaping sales last year of $120 million. As old as the Turkish Republic (founded
in 1923), the company has four production facilities, is one of the country's few remaining active pharmaceutical ingredient
producers, and has products registered in or exports to more than 20 countries. As a result, Mustafa Nevzat is quickly emerging
as one of Turkey's most intrepid drugmakers, parlaying its generics success into manufacturing products for the United States,
Germany, and perhaps soon Japan.
M. Levent Selamoğlu, (All photos are courtesy of EC Reviews.)
Mustafa Nevzat is Turkey's only FDA-approved company for finished products and has been supplying the US since May 2007. By
the end of 2008, the company will have completed construction on its fifth production site, a facility for oncological products
that may export injectables to the US as early as 2009.
In addition, Mustafa Nevzat's sterile injectable manufacturing site has received approval from the United Kingdom's Medicines
and Healthcare products Regulatory Agency.
With 15% of its current revenue based on exports, the company's goal is to have a $100 million in volume going to the US alone
by 2012 and to create more balance between its domestic and foreign sales.
"The domestic pharma market is no longer enough for any company," says M. Levent Selamoglu, Mustafa Nevzat's CEO. "If you
are a generics player, and you have a manufacturing base and if you want to stay in this business, you should be everywhere
in the world."